A14S0X verse

Leading pharmaceutical executive Dr. Robert Karr joins Verseon’s Board of Directors

FREMONT, Calif.--(BUSINESS WIRE)--

Leading pharmaceutical executive and biotech entrepreneur Dr. Robert W. Karr was recently elected as a Non-Executive Director of Verseon, a California-based pharmaceutical company. Dr. Karr had been a member of Verseon’s Scientific Advisory Board, and has helped shape Verseon’s four drug programs in anticoagulation, diabetic macular edema, hereditary angioedema, and oncology. Dr. Karr’s considerable experience across the drug discovery and development process (discovery, preclinical and clinical), as well as his experience in fundraising and partnerships with pharmaceutical companies will be particularly valuable to Verseon as they move their first drug candidates into the clinic in early 2018.

“I am excited to join Verseon’s Board of Directors,” said Dr. Karr. “I have supported the Company since its early years because I recognized the potential impact of Verseon’s disruptive platform on drug discovery. The recent results across the Company’s pipeline, and in particular the progress toward clinical trials, show that Verseon is realizing this potential. I look forward to working with Verseon’s interdisciplinary team.”

Dr. Karr held a range of senior management roles in the pharmaceutical and biotech industry, including Senior Vice President of R&D Strategy at Pfizer, President of Idera Pharmaceuticals, and Vice President of R&D Strategy for Warner-Lambert and G. D. Searle. He completed his internship and residency in internal medicine at Washington University School of Medicine and served as faculty member at both the University of Iowa College of Medicine and Washington University School of Medicine. He received his M.D. from the University of Texas Medical Branch.

Adityo Prakash, Chief Executive Officer at Verseon, commented, “We are delighted to welcome Bob Karr to Verseon’s Board of Directors. For many years he has helped shape Verseon’s drug programs as a member of our Scientific Advisory Board, and we are excited that he has now agreed to serve as a Non-Executive Director. Verseon is entering a significant period as we prepare to advance some of our drug programs into clinical trials. With his wealth of experience and unique understanding of the global pharmaceutical industry, Dr. Karr will provide valuable leadership and strategic insight

For more information about Dr. Karr, please see his Bloomberg profile: http://www.bloomberg.com/research/stocks/people/person.asp?personId=22579628&privcapId=29643

About Verseon

Verseon Corporation (www.verseon.com, AIM: VSN) is a technology-based pharmaceutical company that employs its proprietary, computational drug discovery platform to develop novel therapeutics that are unlikely to be found using conventional methods. The Company is applying its platform to a growing drug pipeline and currently has four active drug programs in the areas of anticoagulation, diabetic macular edema, hereditary angioedema, and oncology.

- Ends -

EN
23/10/2017

Underlying

A14S0Xverse

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on verse

 PRESS RELEASE
Free
A14S0X VERSE

Verseon Showcases Candidates for Next-Generation Diabetic Eye Disease ...

FREMONT, Calif.--(BUSINESS WIRE)-- presented their oral drug candidates for diabetic macular edema (DME) at this week’s 2019 BIO International Convention in Philadelphia. These drug candidates could become the first real alternative to eye injections, the current standard of care for millions of diabetics at risk of vision loss. “Our oral development candidate has the potential to redefine how DME is treated,” said Dr. Anirban Datta, Verseon’s Senior Director of Discovery Biology. “Not only could it replace inconvenie...

June 4, 2019 1 EN
 PRESS RELEASE
Free
A14S0X VERSE

Verseon Presents Oral Drug Candidate for Diabetic Eye Disease That Cou...

FREMONT, Calif.--(BUSINESS WIRE)-- Verseon presented promising preclinical efficacy data for the first development candidate for clinical trials in their diabetic eye disease program at this week’s in Vancouver. This new drug candidate for oral dosing could lead to the first real alternative to eye injections, the current standard of care for millions of diabetics at risk of losing their eye sight. Diabetic macular edema (DME) is a leading cause of adult blindness, affecting about one in three long-term diabetes patients. Wi...

April 30, 2019 1 EN
 PRESS RELEASE
Free
A14S0X VERSE

Verseon Pioneers New Way of Funding Innovation Through Security Token ...

FREMONT, Calif.--(BUSINESS WIRE)-- is launching a security token offering (STO) aiming to set a new standard for the 21st century public offering to a globally connected investor base. To make its STO available to investors around the globe, Verseon will use the technology and services of its subsidiary Using its innovative, computationally driven drug discovery platform, clinical-stage pharmaceutical company Verseon has built a rapidly growing pipeline of unique drug candidates across multiple disease areas. ...

March 18, 2019 1 EN
 PRESS RELEASE
Free
A14S0X VERSE

Verseon Presents Two Precision Oral Anticoagulants with Low Bleeding a...

FREMONT, Calif.--(BUSINESS WIRE)-- Technology-based pharma company Verseon presented two lead candidates from its new class of precision oral anticoagulants (PROACs) at last week’s in Honolulu, HI. The new drug candidates, products of Verseon’s computationally driven drug discovery platform, could become the first anticoagulants suitable for long-term co-administration with antiplatelet drugs for patients with coronary artery disease. Millions of patients worldwide could benefit from safe, long-term therapy combining an oral...

February 11, 2019 1 EN
 PRESS RELEASE
Free
A14S0X VERSE

Verseon Reports First Dosing in Phase 1 Trial on New Precision Oral An...

FREMONT, Calif.--(BUSINESS WIRE)-- Verseon’s phase 1 trial in healthy volunteers, which started dosing last week, could lead to a new treatment standard for millions of cardiac patients who would benefit from long-term therapy with both antiplatelet and anticoagulant drugs. Current anticoagulants (NOACs, novel oral anticoagulants) substantially increase major bleeding events, a potentially fatal side effect, especially when they are administered together with antiplatelet drugs. Preclinical studies found that Verseon’s PROACs...

February 4, 2019 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch